Cargando…

NKT cell adjuvants in therapeutic vaccines against hematological cancers

Immune adjuvants aimed at initiating or re-activating host immunity against poorly immunogenic cancers represent a potential tool for immunotherapy. By employing the natural killer T (NKT) cell agonist α-galactosylceramide in a whole tumor cell therapeutic vaccine approach, we have achieved potent s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mattarollo, Stephen R., Smyth, Mark J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2013
Materias:	Author's View
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583928/ https://www.ncbi.nlm.nih.gov/pubmed/23482240 http://dx.doi.org/10.4161/onci.22615

Ejemplares similares

Invariant NKT cells: Killers and conspirators against cancer
por: Bassiri, Hamid, et al.
Publicado: (2013)

Exploiting invariant NKT cells to promote T-cell responses to cancer vaccines
por: Hunn, Martin K., et al.
Publicado: (2013)

Humanizing mice for the identification of novel anticancer lipids targeting iNKT cells
por: Wen, Xiangshu, et al.
Publicado: (2013)

The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer
por: Demaria, Sandra, et al.
Publicado: (2013)

Targeting MDSCs enhance therapeutic vaccination responses against lung cancer
por: Srivastava, Minu K., et al.
Publicado: (2012)

TG4010: A therapeutic vaccine against MUC1 expressing tumors
por: Limacher, Jean-Marc, et al.
Publicado: (2012)

Prostate cancer: Important steps and considerations in the design of therapeutic vaccines
por: McArdle, Stephanie EB, et al.
Publicado: (2014)

Forging a potent vaccine adjuvant: CpG ODN/cationic peptide nanorings
por: Gungor, Bilgi, et al.
Publicado: (2014)

Co-stimulatory tumor necrosis factor ligands as adjuvants for the development of subunit-based anticancer vaccines
por: Shirwan, Haval, et al.
Publicado: (2013)

Immuno-targeting of pancreatic cancer stem cells: A new therapeutic strategy against a devastating disease?
por: Cioffi, Michele, et al.
Publicado: (2012)

Antibody-based therapeutics against components of the IGF system
por: Feng, Yang, et al.
Publicado: (2012)

The combination of histone deacetylase inhibitors with immune-stimulating antibodies has potent anti-cancer effects
por: West, Alison C., et al.
Publicado: (2012)

Oxygenation to improve cancer vaccines, adoptive cell transfer and blockade of immunological negative regulators
por: Hatfield, Stephen M, et al.
Publicado: (2015)

Immunotherapy with artificial adjuvant vector cells: Harnessing both arms of the immune response
por: Fujii, Shin-ichiro, et al.
Publicado: (2013)

Non-classical MHC Class I molecules regulating natural killer cell function
por: Smyth, Mark J., et al.
Publicado: (2013)

Targeting the IL-12/IL-23 axis: An alternative approach to removing tumor induced immune suppression
por: Smyth, Mark J, et al.
Publicado: (2014)

Could the properties of IL-27 make it an ideal adjuvant for anticancer immunotherapy?
por: Swarbrick, Alexander, et al.
Publicado: (2013)

Cell-penetrating peptides—the Swiss Army knife of cancer vaccines
por: Walker, Paul R., et al.
Publicado: (2015)

Modulating gut immunity and neoplasia with oral cytokine adjuvants
por: Ozbilge, Hatice, et al.
Publicado: (2015)

Targeting cancer stem cells via dendritic-cell vaccination
por: Teitz-Tennenbaum, Seagal, et al.
Publicado: (2012)

Microsatellite instability in hematological malignancies: Hypermutation vs. immune control—who is challenging who?
por: Maletzki, Claudia, et al.
Publicado: (2013)

Naturally circulating dendritic cells to vaccinate cancer patients
por: Bol, Kalijn F., et al.
Publicado: (2013)

Predicting the efficacy of cancer vaccines by evaluating T-cell responses
por: van Duikeren, Suzanne, et al.
Publicado: (2013)

A glypican-3-derived peptide vaccine against hepatocellular carcinoma
por: Sawada, Yu, et al.
Publicado: (2012)

Hypoxia-driven immunosuppression contributes to the pre-metastatic niche
por: Sceneay, Jaclyn, et al.
Publicado: (2013)

Membrane-anchored chemokine fusion proteins: A novel class of adjuvants for immunotherapy
por: Nelson, Peter J, et al.
Publicado: (2013)

The anticancer effects of HDAC inhibitors require the immune system
por: West, Alison C, et al.
Publicado: (2014)

Targeting COX-2 abrogates mammary tumorigenesis: Breaking cancer-associated suppression of immunosurveillance
por: Markosyan, Nune, et al.
Publicado: (2014)

Linking PRMT5 to breast cancer stem cells: New therapeutic opportunities?
por: Chiang, Kelly, et al.
Publicado: (2018)

Immune checkpoint blockade in malignant mesothelioma: A novel therapeutic strategy against a deadly disease?
por: Calabrò, Luana, et al.
Publicado: (2014)

Redirecting neutrophils against bladder cancer cells by BCG and Smac mimetic combination
por: Jinesh G., Goodwin, et al.
Publicado: (2012)

The adenosinergic system in cancer: Key therapeutic target
por: Sorrentino, Rosalinda, et al.
Publicado: (2013)

Personal neoantigen cancer vaccines: The momentum builds
por: Fritsch, Edward F, et al.
Publicado: (2014)

A(2A) blockade enhances anti-metastatic immune responses
por: Beavis, Paul A, et al.
Publicado: (2013)

Enhancing the antitumor effects of radiotherapy with combinations of immunostimulatory antibodies
por: Verbrugge, Inge, et al.
Publicado: (2012)

Preventing surgery-induced NK cell dysfunction and cancer metastases with influenza vaccination
por: Tai, Lee-Hwa, et al.
Publicado: (2013)

Acute myeloid leukemia therapeutics: CARs in the driver’s seat
por: Mardiros, Armen, et al.
Publicado: (2013)

The dual targeting of immunosuppressive cells and oxidants promotes effector and memory T-cell functions against lung cancer
por: Sawant, Anandi, et al.
Publicado: (2014)

Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer
por: Peng, Weiyi, et al.
Publicado: (2013)

Escape from senescence: revisiting cancer therapeutic strategies
por: Zampetidis, Christos P., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gisdva0u8mj2r3ichp4r8mtmkg